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VIRAL HEPATITIS
Histological Changes in HCV Antibody–Positive, HCV
RNA–Negative Subjects Suggest Persistent Virus
Infection
Matthew Hoare,1 William T. H. Gelson,1* Simon M. Rushbrook,1* Martin D. Curran,2 Tracy Woodall,1
Nicholas Coleman,3 Susan E. Davies,4 and Graeme J. M. Alexander1
ItisunclearwhetherhepatitisCvirus(HCV)hasbeeneradicatedorpersistsatalowlevelinHCV
antibody–positive HCV RNA–negative individuals. The natural history and liver histology are
not well characterized. One hundred seventy-two HCV antibody–positive, serum HCV RNA–
negativepatientsunderwentdiagnosticliverbiopsybetween1992and2000andwerefolloweda
median 7 years (range, 5-12). Patients with any possible cause of liver injury other than HCV
were excluded. A single histopathologist scored sections using Ishak criteria. Characterization of
the inﬂammatory inﬁltrate in selected cases used a novel semiquantitative technique and com-
pared with HCV RNA–positive patients and healthy controls. One hundred two patients were
excluded because of a risk factor for liver injury other than HCV. Seventy patients met the study
criteria; four (5.7%) became HCV RNA–positive during follow-up. Sixty-six cases remained
HCV RNA–negative; ﬁve (7.5%) had a normal liver biopsy; 54 (82%) had ﬁbrosis (stage 2 or 3
in 16 (24%)). Nonviremic cases revealed expanded portal tracts (P < 0.05), with fewer CD4
(P < 0.05) and more CD8 cells (P < 0.05) than healthy controls, but were indistinguishable
from HCV RNA–positive cases for these parameters. Lobular CD4 staining, absent in healthy
controls,wasnotedinbothHCVRNA–negativeand–positivecasesandwasmoremarkedinthe
latter (P < 0.05) with a sinusoidal lining cell distribution. Conclusion: Nonviremic HCV anti-
body–positive patients have a liver biopsy that is usually abnormal. Fibrosis was present in most
withsimilarinﬂammatoryinﬁltratetoviremiccases.ThepresenceofaCD8richinﬂammatory
inﬁltrate suggests an ongoing immune response in the liver, supporting the view that HCV may
persistintheliverinthemajorityofHCVRNA–negativecases. (HEPATOLOGY 2008;48:1737-1745.)
See Editorial on Page 1734 H
epatitis C virus (HCV) infection has a preva-
lence of 0.5%-2% in Western countries, with
sustainedviremiain50%-90%ofexposedindi-
viduals.1 Between 5% and 20% of those with viremia
develop cirrhosis eventually2,3 and are then at risk of
chronichepaticfailureandhepatocellularcarcinoma.The
gold standard for investigation of HCV-related disease
remains liver biopsy. Sequential liver biopsies demon-
strate progressive liver ﬁbrosis in more than 50% of sub-
jectswithchronicviremia.3-5Somestudieshavedescribed
the association of strong peripheral T cell responses with
resolution of viremia immediately after acute HCV infec-
tion,6-8 which contrasts with the weak, narrow T cell re-
sponse in viremic HCV carriers.9,10 There have been
fewer studies of the intrahepatic lymphocyte compart-
ment in individuals long after spontaneous resolution of
viremia. There has been resurgent interest in this partic-
ular group following the demonstration of intrahepatic
negative strand HCV RNA, suggesting continued viral
replication,11 leading to the suggestion that such patients
haveoccultor,alternatively,low-levelHCVreplication,12
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1737but the effect of immune responses on viral turnover is
uncertain.
The natural history of HCV-infected patients without
viremia is believed to be excellent but is less well charac-
terized, and histological abnormalities have been de-
scribed in only a limited number of studies.13 A
proportion of nonviremic HCV subjects continue to be
identiﬁed in screening programs, but at present their op-
timal management remains undeﬁned. Until 2000, the
practice in our center was to offer full clinical assessment
including liver biopsy, due to uncertainty of the natural
history of nonviremic subjects.
In this series, the liver biopsy features in a cohort of
HCV antibody–positive, HCV RNA–negative patients
followedinasinglecenterforatleast5yearsaredescribed.
Other causes of liver injury had been excluded carefully,
andtherecognitionthathepaticinﬂammationwasacom-
mon feature in such patients led to further study to char-
acterize the inﬁltrate in a subset of cases. Using
immunohistochemistry, we compared the inﬂammatory
inﬁltrate in a subset of HCV antibody–positive, viremic,
and nonviremic subjects and healthy controls.
Patients and Methods
We conducted a retrospective analysis of patients
known to remain HCV antibody–positive but HCV
RNA–negative (nonviremic) persistently that had under-
gonepercutaneousliverbiopsyinourcenterbetweenJuly
1992 and December 2000. During this period, all pa-
tients who were anti-HCV antibody–positive were of-
fered liver biopsy irrespective of RNA status.
Caseinclusionwasdeﬁnedstrictlytoensurethatexpo-
suretoHCVwastheonlyrecognizedcauseofliverinjury.
All were HCV RNA–negative at presentation, and none
hadundergonetherapywithinterferon.Patientsthatcon-
sumed more than the recommended amount of alcohol
per week (21 U/week in men, 14 U/week in females)
wereexcluded.Patientsinfectedwithhumanimmunode-
ﬁciency virus (HIV) or hepatitis B virus (HBV) and those
withotherrecognizedcausesofchronicliverdiseaseiden-
tiﬁed on blood tests or liver biopsy were also excluded.
Thus, all had a body mass index 30 without risk factors
for insulin resistance; were negative for antimitochon-
drial, antinuclear, and anti–smooth muscle antibodies
withnormalserumimmunoglobulins;hadnoevidenceof
iron overload; and had normal serum 1-antitrypsin,
copper, and ceruloplasmin levels. Patients were analyzed
according to age, sex, and risk factors for acquisition (Ta-
ble 1).
All study patients were followed for a minimum of 5
years (median, 7 years [range, 5-12]) with annual clinical
assessment supported by laboratory tests including liver
function tests, HCV antibody, and HCV RNA.
Thestudywasperformedwiththeapprovalofthelocal
research ethics committee.
HCV Antibody and Polymerase Chain Reaction for
HCV RNA. Immunoglobulin G anti-HCV antibody
was sought using the ADVIA Centaur sandwich immu-
noassay (Bayer, Newbury, UK). Prior to 2003, a nested
blocked based reverse-transcription polymerase chain re-
action (PCR) assay was used to detect HCV RNA. After
2003, HCV RNA was sought using a real-time Taqman
PCR assay, targeting the conserved 5 noncoding region
of the HCV genome and performed on a Rotor-gene
3000 instrument (Corbett Lifescience, Sydney, Austra-
lia). Probit analysis (Stats Direct, www.statsdirect.com)
revealed a limit of detection of 25 IU/mL (95% conﬁ-
dence interval, 6.3-38.6). The detection limit of the
nested reverse-transcription PCR assay was not signiﬁ-
cantly different from the later real-time assay (data not
shown). Patients were only included in this study if a
minimum of 5 (maximum of 12) separate tests at 12-
month intervals had failed to detect HCV RNA.
Routine Liver Histology. Liver biopsies were per-
formedwitha1.9-mmdiameterMenghinineedle.Biopsy
specimens were ﬁxed in 4% neutral buffered formalde-
hyde and embedded in parafﬁn. Four-micrometer sec-
tions were stained with Meyer’s hematoxylin-eosin,
periodic acid–Schiff with diastase pretreatment, Prussian
Blue, a trichrome stain (van Gieson or chromotrope ala-
nineblue),andGomori’sreticulinstain.Allbiopsieswere
examined by a single liver histopathologist (S. E. D.).
Biopsies were classiﬁed according to modiﬁed Ishak crite-
ria14 after assessing the adequacy of the specimen. Histo-
logical activity index represented the sum of interface
hepatitis (0-4), conﬂuent necrosis (0-6), lobular inﬂam-
mation(0-4),andportalinﬂammation(0-4).Fibrosiswas
scored 0 (absent) to 6 (cirrhosis), and steatosis was scored
0-3. Features of steatohepatitis were recorded.
To further characterize the inﬂammation that was
demonstrated at routine histology, the inﬂammatory in-
ﬁltrate was investigated by immunohistochemistry in a
subgroup of cases. A group of 12 nonviremic patients
selected randomly from the original cohort with portal or
lobular inﬂammation between Ishak 1 and 3, was com-
paredwithagroupof13viremicpatientsand18controls.
Liver tissue from viremic HCV patients (n  13) was
matched carefully for age, ﬁbrosis stage, and inﬂamma-
tion grade with the nonviremic patients; these patients
alsometthestrictentrycriteriaforthestudygroup,except
for the presence of HCV RNA in serum and served as a
comparisongroup.Theageandbiopsyfeaturesofthetwo
1738 HOARE ET AL. HEPATOLOGY, December 2008groups were the same except for increased interface activ-
ity in the viremic cohort (Table 2).
Eighteen liver biopsy specimens that were within nor-
mal histological limits according to a liver histopatholo-
gist (S. E. D.) served as controls. In particular, there was
no increase in the portal cell inﬁltrate. The clinical indi-
cation for liver biopsy in that group was investigation of
asymptomatic abnormal liver enzymes. All were negative
for HCV antibody; negative for HBV surface antigen;
had a body mass index 30 without risk factors for insu-
lin resistance; were negative for antimitochondrial, anti-
nuclear, and anti–smooth muscle antibodies with normal
serum immunoglobulins; had no evidence of iron over-
load; and had normal serum 1-antitrypsin, copper, and
ceruloplasmin levels.
Liver Immunohistochemistry. Parafﬁn-embedded,
formalin-ﬁxed liver tissue was cut as 5-m sections to
polylysine-coated slides. Slides were processed for immu-
nohistochemistry as described previously.15 Antigen re-
trieval was achieved by pressure-cooking for 3 minutes in
citratebuffer(pH6.0).Thefollowingmousemonoclonal
antibodies were used: anti-Mcm-2 (generated as reported
previously16), anti-CD3, anti-CD4, anti-CD8, and anti-
perforin (Novocastra, Newcastle, England). Mcm-2, a
marker of cell cycle re-entry, is expressed throughout the
cell cycle but not in quiescent cells. CD3 is a T lympho-
cyte marker. CD4 is expressed on helper T lymphocytes,
and CD8 is expressed on cytotoxic T lymphocytes. Per-
forin expression denotes a T lymphocyte with cytotoxic
potential. Biotinylated goat anti-mouse immunoglobulin
was applied as a secondary antibody. Tonsil was used as a
positive control, and appropriate primary antibody iso-
type served as a negative control on each run.
A streptavidin–horseradish peroxidase system (DAKO,
Denmark) with the substrate diaminobenzidine was used to
develop staining. Slides were counterstained with Harris he-
matoxylin, dehydrated in an ethanol series, and cleared in
xylene. Cover slips were applied with DEPEX mounting
medium (BDH, UK).
A novel approach was used to quantify the results of
immunohistochemistry in an objective fashion. A high
deﬁnition image was taken at 3.5 magniﬁcation using
the Olympus Dotslide system (Olympus Microscopes,
UK) (Fig. 1A). Consecutive sections were used for each
antibodyandthesameﬁeldwasselectedoneachoccasion
based on a reproducibly identiﬁable feature (for example,
aportaltractorcentralvein).Immunohistochemistrywas
assessed using the public domain ImageJ software17 (Na-
tional Institutes of Health, http://rsb.info.nih.gov/ij).
The operator deﬁnes the scale and areas of interest, which
in this series comprised the lobule and the portal tract
(Fig. 1B). Images were transformed into black and white,
andathresholdwasestablishedtoeducatetheprogramto
Table 1. The Demographic Characteristics of 66 Nonviremic, HCV Antibody–Positive Patients
Nonviremic, HCV Antibody–Positive
(n  66) Mean  SD Range
Age (years) 37.6  8.6 21.2–65.7
Male/female ratio (%) 41:25 (62%:38%)
Follow-up (years) 7 5–12
Number of HCV RNA assays per patient 7 5–12
ALT median (normal range) IU/L 31 (40) IQR, 22.25–38.75; range, 8–213
Lobular activity (0–4) 0.82  0.65 0–2
Portal activity (0–4) 0.66  0.60 0–2
Fibrosis (0–6) 1.1  0.73 0–3
Interface activity (0–4) 0.11  0.30 0–1
Conﬂuent necrosis (0–6) 0.05  0.20 0–1
Steatosis (0–3) 0.27  0.57 0–3
ALT, alanine aminotransferase; IQR, interquartile range.
Table 2. Demographic Characteristics of Subjects Studied via Immunohistochemistry
HCV Antibody
and HCV RNA–Positive
(n  13)
HCV Antibody
and HCV RNA–Negative
(n  12)
Healthy Controls
(n  18) Statistic P Value
Age (years  SD) 35.59  11.75 38.83  7.99 48.46  15.70 Kruskal-Wallis test 0.06
Lobular activity (0–4) 2.08  0.29 1.75  0.62 — Mann–Whitney U test 0.11
Portal activity (0–4) 2.00  0.60 1.83  0.58 — " 0.49
Fibrosis (0–6) 1.75  0.75 1.92  1.24 — " 0.69
Interface hepatitis (0–4) 1.50  0.5 0.83  0.72 — " 0.03
Steatosis (0–3) 1.17  0.94 0.58  0.79 — " 0.11
HEPATOLOGY, Vol. 48, No. 6, 2008 HOARE ET AL. 1739identify positive staining of either nuclei or membrane
with each antibody speciﬁcally.
Positive nuclei are identiﬁed readily by size and shape.
To separate overlapping nuclei, a watershed was applied
(Fig. 1C). The results are expressed as the number of
positive nuclei/mm2 of either lobule or portal tract.
Interpretationofmembranousstainingcanbedifﬁcult
in sections where cell density is high (leading to a number
of semiquantitative and subjective scoring systems).
Thus, for assessment of membrane staining the results are
expressed as a proportion; in this study, the numerator
was the area of cells detected as positive membranous
staining by immunohistochemistry (Fig. 1C) and the de-
nominator was the total area of interest (lobule or portal
tract) (Fig. 1D). The proportion of lymphocytes positive
for membrane staining for CD3, CD4, or CD8 was as-
sessed according to either a lobular or portal distribution.
Perforin staining was discrete and cytoplasmic, and the
results are expressed as number of cells positive per mm2
of either lobule or portal tract.
Statistics. Immunohistochemistry results were ana-
lyzed using Prism 5.0 for Windows (Graphpad, San Di-
ego, CA). Multiple groups were analyzed with the
Kruskal-WallistestfollowedbyDunn’smultiplecompar-
ison test. Biopsy Ishak scores were analyzed with the
Mann-Whitney U test. A P value of less than 0.05 was
regarded as signiﬁcant.
Results
Patients. One hundred seventy-two patients positive
for HCV antibody but without HCV RNA in serum (via
PCR) underwent liver biopsy in our center between 1992
and 2000. One hundred two patients were excluded from
the study because of evidence of a further risk factor for liver
injuryotherthanHCVexposure.Currentorpreviousexces-
sive alcohol intake, risk factors for insulin resistance, and
concomitant liver disease, including steatohepatitis, ac-
counted for the majority of those excluded. The remaining
70 patients were followed for a median of 7 years (range,
5-12). All patients retained anti-HCV antibody. However,
during prolonged follow-up, nine of the 70 patients became
HCV RNA–positive. In ﬁve patients, the result was positive
ononlyoneoccasionandwasdeterminedsubsequentlytobe
afalsepositivereaction.However,four(5.7%)patientswere
conﬁrmed repeatedly to be HCV RNA–positive and were
excluded from further analysis. Detection of HCV RNA in
these four cases was not associated with intercurrent illness,
immune suppression, or further exposure to HCV as far as
couldbedeterminedandmayreﬂecteitherdenovoinfection
or reactivation of previously quiescent HCV infection.
Thus,HCVexposureremainedtheonlyidentiﬁedrisk
factor for liver injury in the remaining 66 patients, in
accordance with the strict study criteria. Demographic
Fig. 1. Immunohistochemical analysis using ImageJ software. (A) Representative image obtained via CD3 immunohistochemistry using the
Olympus Dotslide system. The scale bar (500 m) allows absolute areas to be calculated. (B-D) Analysis process for membranous staining. (B)
ImageJ-enhanced 8-bit black and white image with portal tracts cut out to allow separate analysis of both lobular and portal regions. (C) Positive
immunohistochemistry deﬁned in red using a primary antibody-dependent standardized threshold, the area of which provides the numerator for
positive immunohistochemical staining. (D) Threshold that gives a total area for both portal tract and lobular regions; the denominator. Analysis of
nuclear staining is identical to membranous immunohistochemical staining, except that the immunohistochemical numerator is the number of positive
cells. After a watershed is applied to separate overlapping cells, ImageJ calculates the number of positively stained cells using operator-determined
shape and size characteristics.
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acquiredHCVthroughcontaminatedbloodproducts,46
(69.7%)throughinjectingdruguse,andintheremaining
13 (19.7%) patients the source of HCV infection was
undetermined. Ten (15.2%) patients had alanine amino-
transferase levels that were elevated at some time during
the study period, but all other laboratory parameters in-
cluding alkaline phosphatase, gamma glutamyl transpep-
tidase, bilirubin, and platelet counts were within the
normal range consistently in all patients.
Hepatic Fibrosis and Inﬂammation (Figs. 2 and 3).
Onlyﬁveof66(7.5%)patientshadanormalliverbiopsy;
54 of 66 (81.8%) patients had ﬁbrosis.
Stage 0 ﬁbrosis was present in 12 of 66 (18.2%) pa-
tients studied; these included four (33.3%) with grade 1
portal tract inﬂammation and ﬁve (41.6%) with grade 1
lobular inﬂammation.
Stage 1 ﬁbrosis was present in 38 patients (57.6%);
63.2% and 7.9% had grade 1 or 2 portal tract inﬂamma-
tion, respectively; 60.5% and 13.2% had grade 1 or 2
lobular inﬂammation, respectively; and 13.2% had grade
1 interface hepatitis.
Stage2or3ﬁbrosiswaspresentin16(24.2%)patients;
93.7% had grade 1 (75%) and 2 (18.7%) portal tract
inﬂammation; 81.3% had grade 1 (56.3%) and 2 (25%)
lobular inﬂammation; and 18.8% had grade 1 interface
hepatitis.
Bile Duct Damage and Steatohepatitis. Neither
bile duct damage nor steatohepatitis were observed. Con-
ﬂuent necrosis was present in three biopsies (4%), never
exceeding grade 1 (0-6). There was no histological evi-
dence of covert alcohol consumption, consistent with the
strict deﬁnition of the study group.
InﬂammatoryInﬁltrate. Theinﬂammatoryinﬁltrate
was investigated further via immunohistochemistry in 12
nonviremic patients and compared with two control
groups (see above): liver tissue from 13 viremic HCV
patients matched with the nonviremic HCV antibody–
positivegroupand18healthycontrols.Thedemographic
and liver biopsy characteristics of the groups are detailed
in Table 2.
Portal Tracts of Nonviremic HCV Patients Have a
CD8 Rich Inﬁltrate. The area of the portal tract was
expandedinbothgroupswithHCVinfectionwhencom-
pared with healthy controls (P  0.05; data not shown).
There was no difference in the portal tract area between
the two groups of HCV-exposed patients (whether posi-
tive or negative for HCV RNA in serum) who had been
matched (intentionally) for inﬂammation grade.
There were no signiﬁcant differences between patients
and either control group regarding the area of the portal
tract that expressed CD3 (Fig. 4A).
The area of the portal tract that expressed CD4 was
lowerinviremicpatientswithHCVwhencomparedwith
healthy control subjects (P  0.05) (Fig. 4B), but similar
in both HCV-exposed groups.
TheportaltractareathatexpressedCD8wasincreased
signiﬁcantly in both viremic and nonviremic HCV pa-
tients when compared with healthy controls (P  0.05
andP0.0001,respectively(Fig.4C)butsimilarinboth
HCV-exposedgroups.However,thenumberofperforin-
Fig. 2. Fibrosis stage and in-
ﬂammation grade in HCV anti-
body–positive, HCV RNA–negative
subjects (n  66). (A) Pie chart
representation of ﬁbrosis stage by
modiﬁed Ishak criteria (0-6). (B)
Lobular and (C) portal tract inﬂam-
mation according to stage of ﬁbro-
sis.
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groups (P  0.075) (Fig. 4D).
Reduced Lobular CD3 and Perforin Expression in
Nonviremic HCV Patients Compared with Healthy
Controls. The proportion of the lobular area positive for
CD3 in both viremic and nonviremic patients was re-
duced compared with healthy control subjects (P 
0.0132) (Fig. 5A), but was similar in both HCV-exposed
groups.
Therewasanincreaseinthelobularareathatexpressed
CD4 in viremic patients (median, 2.13%; interquartile
range, 1.49-4.49) compared with both nonviremic pa-
tients (median, 0.68%; interquartile range, 0.22-1.16)
(P  0.05) and healthy controls (median, 0.32%; inter-
quartilerange,0.10-1.13)(P0.05)(Fig.5B).However,
review of the staining pattern for CD4 in liver tissue re-
vealedthatmostofthesignallocalizedtosinusoidallining
cells,withtheeffectmostmarkedinpatientswithviremia
Fig. 3. Immunohistochemistry of
the portal inﬂammatory inﬁltrate
from a patient with anti–HCV anti-
body but negative for HCV RNA.
Formalin-ﬁxed, parafﬁn-embedded
tissue was stained for (A) CD4, (B)
CD8, (C) Mcm-2, and (D) perforin.
Scale bars: (B) 200 m; (D) 50
m (inset). Portal tracts are rich in
CD3-positive cells (not shown),
which are more often CD4-positive
than CD8-positive. These cells ex-
press Mcm-2 and perforin rarely.
Fig. 4. Characteristics of the portal
tract inﬁltrate in patients with nonviremic
HCV (n  12), viremic HCV (n  13), and
healthy controls (HC) (n  18) stained for
(A) CD3, (B) CD4, (C) CD8, and (D)
perforin. Results were analyzed using the
Kruskal-Wallis test and Dunn’s multiple
comparison test.
1742 HOARE ET AL. HEPATOLOGY, December 2008(Supplementary Fig. 1A). CD4 expression had a similar
pattern but was less marked in nonviremic patients (Sup-
plementary Fig. 1B) and was rare in healthy controls.
CD4 lymphocytes were detected rarely in both study
groups and when identiﬁed were sinusoidal.
There were no differences between the three study
groups in terms of the lobular area that expressed CD8
(P  0.477) (Fig. 5C). However, perforin expression was
reduced in both viremic and nonviremic HCV patients
compared with healthy controls, but similar in both
HCV-exposed groups (P  0.0314) (Fig. 5D).
Portal Tract Lymphocytes in HCV Infection Are
Mcm-2–Negative Independent of Viremia. Portal tract
cells in both viremic and nonviremic HCV patients had
minimal expression of mcm-2 (Fig. 3C); expression in
both groups was reduced signiﬁcantly compared with
healthy controls (P  0.0004) (Supplementary Fig. 2A).
Increased Lobular Expression of Mcm-2 in Viremic
and Nonviremic HCV Patients. Nonviremic patients
hadsigniﬁcantlygreaterexpressionofMcm-2withinlobular
areascomparedwithhealthycontrols(P0.0005)(Supple-
mentary Fig. 2B). This was almost exclusively conﬁned to
hepatocytes and inﬁltrating inﬂammatory cells were always
negative. There were no differences between the hepatocyte
expression of Mcm-2 between viremic and nonviremic
HCV-positive patients as described.18
Discussion
HCVinfectionleadstochronicviremiainthemajority
of individuals exposed to HCV. The natural history in
this group, the risk factors for progressive injury and the
beneﬁts of antiviral therapy are well established. How-
ever, the clinical status of the minority without viremia
afterexposuretoHCVislessclear.Itisuncertainwhether
this group has resolved infection, with or without long-
term immunity and protection from further exposure to
HCV or, alternatively, low-level viral replication, where
HCV RNA can only be detected within the liver.11,19
Neither the natural history nor the liver histology in this
cohort has been described in detail.
We followed a cohort of HCV-exposed patients with-
out viremia at presentation for a median of 7 years, many
of whom were identiﬁed at a time when there was uncer-
tainty regarding the signiﬁcance of a failure to detect
HCVRNAatﬁrstassessment.Withtheaidofliverbiopsy
in all of these patients and critically, careful subsequent
exclusionofallpatientswithapossiblealternativecauseof
chronic liver disease, we have been able to challenge the
view that nonviremic HCV-exposed patients have re-
solved infection. First, viremia was detected eventually in
5.7% of this group, a proportion that may increase with
time; second, just 7.5% of patients had normal histology;
third, 92% of patients had inﬂammation within the liver,
while 82% had ﬁbrosis, which in about a quarter would
have been sufﬁcient to prompt consideration of antiviral
therapy if the patients had been viremic; ﬁnally, when
cases without viremia were compared with viremic pa-
tients matched for grade of inﬂammation and stage of
ﬁbrosis, the phenotype of the inﬂammatory inﬁltrate was
similar and distinct from that in healthy controls.
Thesedataareconsistentwiththehypothesisthatnon-
viremic patients exposed to HCV have chronic low-level,
probably hepatic viral replication that is associated with a
lower risk of progressive liver injury compared with vire-
Fig. 5. Characteristics of the lobular
inﬁltrate in patients with nonviremic HCV
(n  12), viremic HCV (n  13), and
healthy controls (HC) (n  18). Biopsies
were stained for (A) CD3, (B) CD4, (C)
CD8, and (D) perforin. Results were ana-
lyzed using the Kruskal-Wallis test and
Dunn’s multiple comparison test.
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the histological abnormalities, including as yet unknown
viral infections or nonalcoholic fatty liver disease without
histological features of steatohepatitis.
Serumfrom80HCVRNA–negativepatientswassub-
jectedtoultracentrifugationbeforerepeatingtheassayfor
HCV RNA; HCV RNA was still not detected (Rolfe K
andCurranMD,personalcommunication).Theﬁndings
arethusconsistentwithseveralstudiesthathavedescribed
the detection of HCV RNA in liver tissue in nonviremic
HCV-exposedindividuals.11,19-21Thisviewwouldalsobe
consistent with a failure to demonstrate sterilizing immu-
nity against HCV in humans or primates,22 and it is pos-
sible that HCV is a lifelong infection in many more cases
than has been supposed hitherto. Perhaps the most im-
portant question to address in this cohort is why such
cases have lower levels of viral replication. The long-term
histology in those treated successfully with pegylated in-
terferon- and ribavirin will be of interest in this context,
because loss of the inﬂammatory inﬁltrate would be con-
sistent with eradication of HCV, while ongoing inﬂam-
mation, as in this series, would be indicative of low-level
HCV replication.
Inﬂammation in the liver is a sensitive indication of
hepatic disorder, but indirect evidence of infection. The
best evidence of infection in nonviremic HCV-exposed
patients would be the demonstration of HCV genomic
material and replicative intermediates in the livers of such
cases.Bothpositive-andnegative-strandHCVRNAhave
been identiﬁed in the liver tissue of nonviremic HCV
patients with normal alanine aminotransferase values11;
thatstudyalsodemonstratedthatHCVRNAwaspresent
in serum after ultracentrifugation.20 This suggests non-
viremicHCVpatientsaredeﬁnedbyinsensitivetests.Ina
series of patients from the same authors with HCV RNA
present in liver but without viremia, 15% had ﬁbrosis,
including 4% with cirrhosis.13 This contrasts with 82%
withsomedegreeofﬁbrosisinourseries,adifferencethat
may be explained by the longer duration of follow-up in
this series compared with that of the Spanish group.11
Immunohistochemical analysis was revealing. There
were consistent differences between HCV-exposed cases
(irrespective of viremic status) and healthy controls; in
contrast, no differences were detected between viremic
and nonviremic HCV-exposed patients matched for in-
ﬂammation for any other parameter. Thus, the portal
tracts were expanded with nonproliferating (Mcm-2–
negative) T cells enriched with CD8 T cells and de-
pletedofCD4TcellsinHCV-exposedpatientsrelative
to healthy controls. However, the proportion of cells ex-
pressingperforin,amarkerofcytotoxicpotential,waslow
andsimilarinallthreegroups.23Thelobularinﬁltratewas
CD3 T cell–depleted and perforin-negative in both
HCV-exposed groups relative to healthy controls.
Mcm-2 expression, a marker of cell cycle entry, was
increased in hepatocytes in both HCV study groups. A
previous study indicated that hepatocytes in HCV-ex-
posedpatientshadevidenceofcellcycleentrywithoutcell
cycle progression—a state of cell cycle arrest—that corre-
lated with ﬁbrosis stage.18 Many viruses replicate more
efﬁciently in cell cycle–arrested host cells,24 and Mcm-2–
positive hepatocytes may be either HCV-infected or re-
generating in response to ongoing liver injury. In either
case, the ﬁnding is indicative of an ongoing liver insult in
both viremic and nonviremic HCV-exposed groups.
Stringent selection of nonviremic HCV-exposed pa-
tients with HCV as the only risk factor for liver injury
revealedabnormalliverhistologyinalmostallcases.How
should such cases be managed? For now, it might be wise
to continue to follow such cases to determine whether
HCV RNA will be detected eventually and to determine
thenaturalhistoryinthiscohort.Inthefuture,testingfor
HCVinserumortissuemayimprove,andtheproportion
of HCV RNA–negative patients may fall. Intervention
with antiviral therapy cannot be justiﬁed based on our
current knowledge of the natural history; however, it will
be intriguing to determine the late histology in HCV
RNA–positive cases treated successfully to see whether
these revert to normal histology or something more akin
to the ﬁndings in the nonviremic group in this series.
However, a possible role for HCV in nonviremic patients
with a second risk factor for liver injury does need to be
addressed, and it is possible that the threshold for inves-
tigating such cases more thoroughly will be reduced.
Whether this group is analogous to patients with oc-
cult HBV infection25 who can experience reactivation of
viral replication in the face of profound immunosuppres-
sion26 is not known. Previous studies comparing rates of
HBV and HCV reactivation suggest that it is much less
commonwithHCVandindeedmaynotoccur;inastudy
of 305 patients receiving corticosteroid containing che-
motherapyforhematologicalmalignancy,therewerenine
reactivations of HBV infection but no reactivation of
HCV viremia, despite a four-fold higher prevalence of
nonviremic HCV than HBV.27 A more analogous situa-
tion may be the outcome of antiviral therapy, where a
small proportion of individuals eventually become HCV
RNA–positive despite sustained virological response
(SVR). In one study of individuals who achieved SVR
after previously failing an initial course of antiviral ther-
apy,theviralrecurrencerateafterSVRwas11.3%.28Fur-
thermore, viral RNA can be detected in peripheral blood
lymphocytes and macrophages from those individuals
who have successfully achieved SVR.29
1744 HOARE ET AL. HEPATOLOGY, December 2008An unexpected but consistent observation was that
CD4expressioninthelobulewasprominentinsinusoidal
lining cells in HCV-exposed patients. The pattern was
most consistent with endothelial expression, and expres-
sionwasmostmarkedinviremicpatients.Themajorityof
CD4stainingwassinusoidal,whichcauseddifﬁcultywith
thesemiautomatedcountoflymphocytesthatwerethere-
fore assessed via more conventional means. The signiﬁ-
cance of sinusoidal lining cell CD4 expression will be
pursued in a separate study. CD4 staining has been dem-
onstrated in both glomerular and brain endothelial tissue
in HIV-1 infection.30,31 In the latter study, brain endo-
thelial cells expressed both CD4 and chemokine recep-
tors, suggesting a permissive role in HIV infection.30
In conclusion, we have identiﬁed a cohort of individ-
ualswithnoriskfactorforliverinjuryotherthanprevious
HCV exposure. We have demonstrated that these pa-
tients with nonviremic HCV have a CD8 rich hepatic
inﬂammatory inﬁltrate and the great majority have evi-
dence of hepatic ﬁbrosis.
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